Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ARV-102 in Neurodegenerative disease, Parkinson's disease. The expected timing is based on the latest available company guidance and may change.
2/20/24- Dosed first participant. 1/10/25- Present SAD data at AD/PD conference on April 1-4, 2025. 4/4/25- Complete SAD enrollment w/ initial data in 2025. Initiate MAD cohort enrollment in 2025. 10/5/25- Presented clinical data at MDS '25. 11/05/25:- Positive Ph1 biomarker data; initiated multiple-dose PD cohort. Initial multiple-dose data expected 2026. 02/24/26:- Multiple-dose Ph1 Parkinson's cohort data accepted for AD/PD March 2026 oral presentation, including safety, PK, degradation and biomarkers. 03/11/26:- Phase 1 multiple-dose PD data will be presented at AD/PD 2026 on March 18, 2026. 03/18/26:- Phase 1 multiple-dose PD data presented at AD/PD 2026; CSF LRRK2 reduced; well tolerated. 05/12/26:- Ph1 Parkinson's biomarker data showed >50% CSF LRRK2 degradation; additional biomarker data expected H2 2026. 08/04/26:- Additional Ph1 Parkinson's biomarker data expected at MDS in October 2026.
Verification
Confirm timing and program details against the company announcement or filing.